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FollowingthediscoveryofendotoxinsbyRichardPfeiﬀer,suchbacterialproductwasassociatedtomanyseveredisordersproduced
by an overwhelming inﬂammatory response and often resulting in endotoxic shock and multiple organ failure. However, recent
clinical and basic sciences investigations claimed some beneﬁcial roles of typical as well as atypical endotoxins. The aim of this
paper is to focus on recent data supporting a beneﬁcial activity of both typical and atypical endotoxins. Such novel perspective
looks promising for development of new drugs for prevention and therapy of several human diseases.
1.Introduction
The Erinyes were three netherworld goddesses depicted as
ugly, winged women with hair, arms, and waists entwined
with poisonous serpents and personiﬁed the tormenting
madness inﬂicted upon a patricide or matricide. They could
make people suﬀer, and a nation harbouring such people
could experience dearth, and with it hunger and disease.
On the contrary, the Charites, also commonly known as the
Graces, were three goddesses daughters of Zeus and named
Aglaia, Thalia, and Euphrosyne. They were often associated
with grace, beauty, adornment, mirth, festivity, dance, and
songs of revel [1].
The endotoxins of Gram-negative bacteria are lipopoly-
saccharides (LPSs), which are vital to both the structural and
functional integrity of the bacterial outer membrane [2, 3].
In the ﬁrst reports on endotoxin by Pfeiﬀer (1892) and
Centanni (1894), only one side of the coin (the toxic activity)
hasbeenconsidered[4].LewisThomasreportedthereaction
of higher animals (including humans) to endotoxins as
“... a uncontrolled and auto-destructive behaviour of the
host, leading to the consideration of endotoxin as a venom.
All this seems unnecessary, panic-driven. There is nothing
intrinsically poisonous about endotoxin, but it must look
awful,orfeelawful,whensensedbycells...”(LewisThomas,
Germs, 1974). However, endotoxins may behave not only as
Erinyes but also as Charites. Indeed many LPS activities are
being increasingly revealed to be beneﬁcial to the host. Some
of such beneﬁcial activities have been published a few years
after endotoxin discovery, including the inhibitory eﬀects
on human sarcoma studied (since late 1890s) by William
Bradley Coley, who used killed Serratia marcescens, and the
successful therapy of lethal tertiary syphilis reported by the
1927 Nobel laureate Julius Wagner von Jauregg, who used
diﬀerent types of microbial suspensions [4].
The purpose of this paper is to focus on recent data
supporting beneﬁcial activities of both typical and atypical
endotoxins.
2. Chemistry of Typicaland Atypical
Lipopolysaccharides
The lipid A, the core oligosaccharide, and the O-antigen
polysaccharide chain are the three domains usually found in
an LPS molecule.
The innermost, hydrophobic region, lipid A, is responsi-
ble for the major toxic and beneﬁcial properties of bacterial
endotoxins [2]. Lipid A is the least variable part of the
molecule among the diﬀerent species of a genus, and its
structure generally consists of a diglucosamine backbone
substituted with varying numbers (usually four to seven) of
ester- or amide-linked fatty acids.
Phosphate and/or other substituents are linked to car-
bons at the C-1 and C-4  positions of the glucosamine
disaccharide [3]( Figure 1). A 2-keto-3-deoxyoctonate (Kdo)2 Mediators of Inﬂammation
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Figure 1: Balance between beneﬁcial and immunopathological roles of LPSs.
unit links the lipid A to a core oligosaccharide (OS)
composed of about 10 sugar residues. The core is linked
to a third outermost region of a highly immunogenic and
variable O-chain polysaccharide (PS) or O-antigen made up
of repeating OS units. The latter region of the LPS molecule
is responsible for bacterial serological strain speciﬁcity and
is present only in smooth-type bacteria. The core region
of enterobacterial LPS includes an outer portion, distal
from lipid A (proximal to the O-polysaccharide chain),
and an inner portion directly linked to the lipid A. The
complete outer core region (Ra-structure) mainly consists
of hexoses and hexosamines, whereas inner core region is
composed of KDO and heptose. The so-called rough-type
bacteria produce LPSs lacking O-antigens [2, 3]. A successive
truncation of Ra-structure LPSs associated with speciﬁc
alterations of core oligosaccharide biosynthesis in diﬀerent
Salmonella strains (R-mutants) results, respectively, in the
Rb, Rc, Rd, and Re core structures. The last structure, which
contains only lipid A and KDO residues, is a minimal LPS
structure. The lipooligosaccharides (LOSs) consist of lipid A
and an oligosaccharide core. The structural organization of
LOS allows us to assign them to the group of intermediate
molecules between typical R- and S-LPS structures.
The lipooligosaccharides (LOSs) contain a recognizable,
well-conserved inner core (including KDO and heptose
residues) from which extend one or two/three mono- or
oligosaccharide branches (such as α-, β-, and γ-chains in
Neisseria LOSs), that exhibits serological speciﬁcity [3].
In classical LPSs, the core provides an acceptor for O-
polysaccharide, on the contrary in LOSs (distinct from R-
LPS) the core is destined to terminate without O polysaccha-
ride addition [2, 3].
LOSs are identiﬁed in such Gram-negative bacteria as
Bordetella pertussis, Neisseria meningitidis, Neisseria gonor-
rhoeae, Haemophilus inﬂuenzae, Haemophilus ducreyi, Burk-
holderia (Pseudomonas) multivorans, Burkholderia (Pseu-
domonas) cenocepacia, Alteromonas addita KMM 3600T, and
Campylobacter jejuni [2, 3].
Atypical LPSs reportedly exhibit a lipid A chemistry
which is diﬀerent from archetypal structure found in
Escherichia coli and Salmonella. Namely, atypical lipids A
from diﬀerent bacteria have the same general structure,
but diﬀer in the head-group substituents (e.g., phosphate
groups) and in the number, distribution, and composition
of fatty acids [2, 3].
In addition to the presence of fatty acids with hydro-
c a r b o nc h a i nl o n g e rt h a n1 4c a r b o na t o m s ,t h ec h a r g eo f
lipids A from Helicobacter pylori, Porphyromonas gingivalis,
Francisella tularensis was lower than the charge of lipids A
from E. coli and compound 506, which could also aﬀect theMediators of Inﬂammation 3
binding. The low aﬃnity of LPS binding with LBP and/or
sCD14 is likely to inﬂuence the rate of endotoxin delivery
to membranes of target cells and as a result to decrease the
eﬀectiveness of LPS signalization [2].
Matera et al. [5] reported that Bartonella quintana LPS
exhibited a migration pattern of the deep rough chemotype.
Bartonella henselae has been found to exhibit a deeply
atypical LPS with an approximate molecular weight of 5000
and with a Lipid A containing an acyloxyacyl residue 16:0[3-
O(28:0(27-OH))] [6].
Therefore, LPS of Bartonella henselae has a deep-rough
structurewithoutanO-chainpolysaccharideandcontainsan
unusual penta-acylated lipid A with a long-chain fatty acid.
TheabsenceofO-sidechaincouldconceivablydecreasecom-
plement ﬁxation and provide a degree of serum resistance
on Bartonella, but this possibility has not been explored. The
unusual fatty acid composition renders Bartonella henselae
endotoxin at least 1000-fold less potent at Toll-like receptor
(TLR)4 activation (as measured by IL-8 production), as
compared with LPSs from Salmonella [3, 6].
LPS also serves as one of the primary targets of the
innate arm of the mammalian immune system, whose Toll-
like receptors (TLRs) are the primary Pathogen Recognition
Receptors (PRR). A wealth of publications indicated TLR4
andTLR2asthereceptorsinvolvedintherecognitionofmost
of the LPS studied [2, 3, 6, 7].
LPSs are known as endotoxins, which cause the promi-
nent pathophysiological symptoms associated with sepsis
and septic shock, that is, fever, leukopenia, hypotension,
disseminated intravascular coagulation, and multiple organ
failure [2, 3]. The well-known typical LPS from enteric
bacteria, such as Escherichia coli and Salmonella enterica,a r e
highly potent molecules with regard to their biological, that
is, endotoxic activities [6].
3.Beneﬁcial Activitiesof TypicalLPSs
Naturally occurring (often typical) LPSs modulate the
immune system of higher vertebrates in order to keep
pathogens away and to avoid the possibility of sapro-
phytes/commensals to become invaders (translocation);
moreover, it has been demonstrated that the immune system
is dependent on certain microbial products including LPSs
for normal development [7].
Epidemiology studies in young children have found
that LPS exposure at home is inversely correlated with
the development of atopic diseases, following the “hygiene
hypothesis” for allergic disorders [8].
The growing prevalence of broadly diﬀused chronic,
inﬂammatory, and degenerative diseases in the industrial-
ized world (allergic illnesses, diabetes and other metabolic
disorders, inﬂammatory bowel diseases and, within the
central nervous system (CNS), demyelinizing inﬂammatory
pathologies, as well as stroke) might ask for a broadening of
such “hygiene hypothesis” [9], which should also include the
above reported chronic/inﬂammatory diseases [10].
In an asthma model, nonobese diabetic (NOD) mice
were immunized intraperitoneally on day 0 with ovalbumin
(OVA) in presence of alum, challenged one week later with
3 consecutive OVA aerosol administrations and analyzed
24hrs after the last challenge. Following this protocol,
mice presented allergic inﬂammation and abnormal lung
function. Allergic inﬂammation resulted in an increase of
cell recruitment including eosinophils in the BALF, and
of cytokine and chemokine production, IL-4, and eotaxin,
respectively, in the lung. Mice treated with TLR agonists,
particularly LPS, showed a decreased eosinophilia and IL-4
and eotaxin production as compared to control mice [11].
In a NOD mice experimental model, the eﬀect of TLR
ligands, including LPSs, on development of spontaneous
diabetes was evaluated. In NOD protected (LPS-treated)
animals, the histological analysis of the pancreas showed
a reduction in destructive islet inﬁltration (i.e., invasive
insulitis). This form of insulitis is associated with active
destruction of insulin-secreting β-cells; this is the point in
time, where the ﬁrst mice showing overt hyperglycemia can
be seen. It appears that in the case of LPS treatment a control
of insulitis progression and hyperglycemia can be observed
[11, 12].
To address the intricate relationship between gut micro-
biota and host cells, colitis was induced in C57BL/6J
mice with dextran sodium sulfate (DSS) or by transferring
CD45Rb(hi) T cells into RAG1−/− mice. Colitis severity
was assessed by disease activity index (DAI) and histology.
The eﬀect of anti-TLR4 antibodies (Ab) on the inﬂam-
matory inﬁltrate was determined by cell isolation and
immunohistochemistry. Mucosal expression of inﬂamma-
tory mediators was analyzed by real-time PCR and ELISA.
Blocking TLR4 at the beginning of DSS administration
delayed the development of colitis with signiﬁcantly lower
DAI scores. Anti-TLR4 Ab treatment decreased macrophage
and dendritic cell inﬁltrate and reduced mucosal expression
of CCL2, CCL20, TNF-alpha, and IL-6. Anti-TLR4 Ab
treatment during recovery from DSS colitis resulted in
defective mucosal healing with lower expression of COX-
2, PGE(2), and amphiregulin. In contrast, TLR4 blockade
had minimal eﬃcacy in ameliorating inﬂammation in the
adoptive transfer model of chronic colitis. Therefore, anti-
TLR4 therapy may decrease inﬂammation in IBD but may
also interfere with colonic mucosal healing [12].
Deﬁcient TLR signaling may cause an imbalance in
commensal-dependent homeostasis, facilitating injury and
leadingtoinﬂammatoryboweldisease.Accordingly,systemic
administrationofaTLR4-blockingantibodyimpairsrestora-
tion of tissue integrity during DSS-colitis, despite limiting
exaggeration of acute inﬂammatory responses induced by
recruited cells. Several recent studies suggest that TLR
signaling exerts many important cytoprotective functions
in the intestinal epithelium (and adjacent cell subsets),
w h i c ha r er e q u i r e df o rb a r r i e rp r e s e r v a t i o n ,c e l ls u r v i v a la n d
stability, and restitution, including, for example, inhibition
of apoptosis, migration, and proliferation [13, 14].
Thus TLR4 agonists such LPS could be beneﬁcial in
colonic mucosal healing during IBD.
Animals exposed to LPS as neonates displayed induc-
tion of IL-10 within the CNS, and there was a robust
inverse correlation between experimental autoimmune4 Mediators of Inﬂammation
encephalomyelitis severity and the frequency of CNS-
inﬁltrating FoxP3+ T lymphocytes. These observations were
supported by reduced FoxP3 expression in brain tissue from
multiple sclerosis (MS) patients compared with non-MS
patients [15].
A small dose of LPS given systemically confers ischemic
protection in the brain, a process that appears to involve
activation of an inﬂammatory response before ischemia. LPS
preconditioning in the brain shares some hallmarks that are
characteristics of ischemic preconditioning in other organs.
Interestingly, it has been reported that pretreatment of
animalswithLPSincreasesmyocardialfunctionalrecoveryin
ischemia/reperfusion heart injury model. Such LPS-induced
beneﬁcial eﬀect has been shown to be mediated through
inhibition of NF-κB via increase of HSP70. These include
delayed induction of tolerance after preconditioning and
dependence on “de novo” protein synthesis. The systemic
route of LPS administration and the induction of some
systemic changes are unique aspects of LPS preconditioning
that might oﬀer some clinical advantages [14–16]. Also, the
very recent paper by Mouihate et al. [17], underlined that
early postnatal LPS exposure remodulates neuroimmune
axis allowing enhanced activation of a novel prostaglandin-
mediated activation of the hypothalamic-pituitary-adrenal
(HPA) axis brought about by increased constitutive expres-
sion of TLR4 and COX2 [17]. Reprogramming the neuroim-
mune axis during infancy might be beneﬁcial in the rest of
animal and human life. Such LPS-driven tight regulation of
overwhelming or inappropriate immune system activation
would pay oﬀ during acute systemic inﬂammatory reaction
(e.g., sepsis/septic shock) or severe allergic disorders (e.g.,
asthma attack) in adult life.
4. Beneﬁcial Effects of AtypicalLPSs
Some bacteria (e.g., Bartonella, Yersinia, Rhodobacter, Chro-
mobacterium) contain an atypical LPS with low endotoxic
activity and/or prominent antagonistic eﬀect on LPSs from
enteric bacteria [2, 17–19].
Coevolution of organisms bearing a deeply modi-
ﬁed/atypical LPS with a vertebrate host would be beneﬁcial
to both of them. Indeed the microorganisms factors includ-
ing LPS may reduce/inhibit the inﬂammatory potential
of same tissue/district (respiratory and digestive mucosal,
CNS).
Rough mutants of Yersinia enterocolitica exhibited atyp-
ical LPS and attenuated virulence and lack of ability to
colonize organs as spleen and liver. Even more interestingly
such mutants showed a substantial impairment of several
other virulence factors, which depend on a full structure of
LPS for proper function and/or expression [20]. Therefore,
these strains might be exploited for preparation of vaccines
or adjuvants.
Similarly to other atypical LPS-bearing bacteria also Bar-
tonella spp. are endowed with anti-inﬂammatory activities
which might be exploited for medical purposes [18, 19].
Bartonella spp.LPS have been found to behave in a
manner that is substantially diﬀerent from other LPSs from
saprophytic, commensal, and pathogenic microorganisms.
Matera et al. [5] reported that B. quintana LPSs exhibited
a migration pattern of the deep rough chemotype, a strong
reactivity following the chromogenic Limulus amoebocyte
lysate test and a very low cytokine release from human whole
blood samples. In human leucocytes or in endothelial cells
[21], as well as in a rat model [22], B. quintana LPS was not
able to induce signiﬁcant levels of blood TNFα.M o r e o v e r ,
B. quintana LPS induced an increase in the white blood cell
count without a substantial change in heart rate, hemat-
ocrit, platelet count, or blood pressure [22]. Remarkably,
Bartonella quintana LPS possesses antagonistic properties
for TLR4 and does not activate TLR2 [18, 19]. However,
the physical-chemical features of B. quintana LPS warrant
further investigations for a more in-depth knowledge of the
structure-activity relationship.
The atypical LPS attributes undoubtedly contribute
to the establishment and maintenance of mild although
persistent infection, since the bacterium’s major surface
componentissubinﬂammatoryandantagonistictothehost’s
innateimmuneresponse.Interestingly,long-chainfattyacids
are a conserved feature in the LPS of intracellular bacteria
that establish long-term symbioses with their host, including
Legionella, Chlamydia, and closely related rhizobia [2].
The control of inﬂammatory illnesses and the decrease
of allergic/atopic disorders might be obtained by the admin-
istration of such antagonistic LPS species. Also the control
of experimental rheumatic disease has been obtained by
administration of TLR4 antagonist LPS from B. quintana
[23]. However, impaired NF-κB translocation by LPS pre-
treatment was also observed in TLR4-transfected overex-
pressing cells, suggesting that downregulation of TLR4 or
TLR4antagonismarenotnecessaryeventsinimpairedsignal
transduction in LPS-tolerant cells/tissues [24] and pointing
to downstream site(s) of regulation and control of TLRs-
dependent cascades carried out by LPSs and other bacterial
products [7].
The complex population of microbes that we harbor
within our mucosal cavities is not just passive bystanders,
rather these organisms seem to actively shape our immune
system responses both along the mucosal surface and in very
remote tissues/organs [11].
Therefore, we suggested that some pivotal virulence
factors, such as LPSs, control broad and increasingly diﬀused
chronic, inﬂammatory, and degenerative diseases during the
human evolution [25].
More interestingly some atypical LPSs could be plausible
candidates to be developed into useful drugs for many
diseases such as allergic illness, inﬂammatory bowel disease,
and demyelinizing pathology of CNS [25].
5.LPSDerivativesas AdjuvantsandVaccines
Furthermore, enzymes involved in Lipid A biosynthe-
sis/modiﬁcation [3] not only provide access to new lipid
A derivatives that may be useful as adjuvants or endotoxin
antagonists, but also can be exploited for generating novel
live bacterial vaccines. Heterologous expression of lipid A
modiﬁcation enzymes like LpxE, LpxF, LpxR, or PagL inMediators of Inﬂammation 5
pathogens such as Salmonella might attenuate these bacteria
by altering lipid A structural elements recognized by the
TLR-4/MD2 complex [3].
Monophosphoryl lipid A (MPL) has been obtained from
Salmonella minnesota R595 by removal of core KDO, one
phosphate and one acyl chain from disaccharide backbone.
MPL is among the recently licensed adjuvants and is used
in combination with alum in recently approved vaccines for
human papillomavirus and hepatitis B virus. Adjuvants can
modify the delivery of the antigen or act as immunopo-
tentiators, inﬂuencing both the amount and the quality of
the adaptive immune response. Delivery can be modiﬁed
through the slow release of antigen and enhancement of
uptake by APCs in emulsions and liposomes, for example,
whereas immunopotentiators act through the activation of
the innate immune system [26].
6. Conclusions
While it seems clear that the microbiota inﬂuences progres-
sion and/or prevention of disease, the mechanism by which
it can accomplish this task remains to be assessed. We have
presented evidence that there is an intimate relationship
between host and microbe that involves bacterial LPSs and
host intricate mechanisms.
As many other molecules in biology, LPSs appeared as a
“double-edged sword” [19].Beneﬁcialactivityofbothtypical
and atypical endotoxins look promising for the development
of new drugs for prevention and the therapy of several
human diseases.
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